QT Imaging Secures Israeli Regulatory Approval for Radiation-Free Breast Scanner
Event summary
- QT Imaging received Israeli Ministry of Health regulatory registration for its Breast Acoustic CT™ Scanner, valid through February 2028.
- The approval allows commercialization in Israel and is based on existing U.S. FDA clearance.
- QT Imaging will collaborate with Rambam Health Care Campus for a clinical study on hereditary breast cancer risk populations.
The big picture
QT Imaging's regulatory win in Israel positions it to tap into a market known for advanced breast cancer research and precision medicine. The collaboration with Rambam Health Care Campus underscores the strategic importance of clinical validation in hereditary cancer populations, where Israel has established expertise. This approval could serve as a springboard for broader international commercialization efforts.
What we're watching
- Clinical Validation
- How the Rambam collaboration will impact QT Imaging's ability to generate clinical evidence in hereditary breast cancer populations.
- Market Expansion
- The pace at which QT Imaging can scale commercialization beyond Israel, leveraging its radiation-free technology differentiation.
- Regulatory Strategy
- Whether the Israeli approval will serve as a template for other international markets with stringent health regulations.